• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Burning Rock Biotech Limited (BNR) Stock Price, News & Analysis

Burning Rock Biotech Limited (BNR) Stock Price, News & Analysis

Currency in USD Disclaimer

$7.16

$0.2

(2.87%)

Day's range
$6.61
Day's range
$7.18
50-day range
$2.65
Day's range
$7.47
  • Country: CN
  • ISIN: US12233L1070
52 wk range
$2.62
Day's range
$9.99


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -6.10
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (BNR)
  • Company Burning Rock Biotech Limited
  • Price $7.16
  • Changes Percentage (2.87%)
  • Change $0.2
  • Day Low $6.61
  • Day High $7.18
  • Year High $9.99

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$8.11
  • Trailing P/E Ratio -0.96
  • Forward P/E Ratio -0.96
  • P/E Growth -0.96
  • Net Income $-653,689,000

Income Statement

Quarterly

Annual

Latest News of BNR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Burning Rock Biotech Limited Frequently Asked Questions

  • What were the earnings of BNR in the last quarter?

    In the last quarter Burning Rock Biotech Limited earnings were on Tuesday, December, 3rd. The Burning Rock Biotech Limited maker reported -$0.50 EPS for the quarter, beating analysts' consensus estimates of -$1.41 by $0.91.

  • What is the Burning Rock Biotech Limited stock price today?

    Today's price of Burning Rock Biotech Limited is $7.16 — it has increased by +2.87% in the past 24 hours. Watch Burning Rock Biotech Limited stock price performance more closely on the chart.

  • Does Burning Rock Biotech Limited release reports?

    Yes, you can track Burning Rock Biotech Limited's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Burning Rock Biotech Limited stock forecast?

    Watch the Burning Rock Biotech Limited chart and read a more detailed Burning Rock Biotech Limited stock forecast to see what analysts suggest you do with its shares.

  • What is Burning Rock Biotech Limited stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Burning Rock Biotech Limited stock ticker.

  • How to buy Burning Rock Biotech Limited stocks?

    Like other stocks, BNR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Burning Rock Biotech Limited's EBITDA?

    Burning Rock Biotech Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Burning Rock Biotech Limited’s financial statements.

  • What is the Burning Rock Biotech Limited's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -1.2163126704, which equates to approximately -121.63%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Burning Rock Biotech Limited stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Burning Rock Biotech Limited's financials relevant news, and technical analysis. Burning Rock Biotech Limited's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Burning Rock Biotech Limited stock currently indicates a “sell” signal. For more insights, review Burning Rock Biotech Limited’s technical analysis.

  • A revenue figure for Burning Rock Biotech Limited for its last quarter?

    Burning Rock Biotech Limited published it's last quarterly revenues at $128.64 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.